ID   HepG2-GS-CYP3A4
AC   CVCL_8560
SY   GS-3A4-HepG2
DR   Wikidata; Q54882851
RX   PubMed=15903254;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 2637; CYP3A4.
CC   Transfected with: HGNC; 4341; GLUL.
CC   Discontinued: JCRB; NIHS0617; true.
CC   Derived from sampling site: Liver.
ST   Source(s): JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,13
ST   D16S539: 12
ST   D5S818: 11,12
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 18
RX   PubMed=15903254; DOI=10.1021/bp049757a;
RA   Omasa T., Kim K., Hiramatsu S., Katakura Y., Kishimoto M., Enosawa S.,
RA   Ohtake H.;
RT   "Construction and evaluation of drug-metabolizing cell line for
RT   bioartificial liver support system.";
RL   Biotechnol. Prog. 21:161-167(2005).